EP Patent

EP3851142A1 — Nozzles for nasal drug delivery

Assigned to Impel Pharmaceuticals Inc · Expires 2021-07-21 · 5y expired

What this patent protects

A nozzle for use in delivering an intranasal dosage form. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. A nozzle body defining a plurality of channels is provided. The channels are disposed along …

USPTO Abstract

A nozzle for use in delivering an intranasal dosage form. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. A nozzle body defining a plurality of channels is provided. The channels are disposed along the longitudinal axis and are symmetric about a circle around the longitudinal axis, and the proximal end of each of the plurality of channels is configured to be in fluid communication with the drug product inlet such that the received mixture passes through each of the channels. An outlet orifice is disposed at the end of each channel such that the outlet orifices generate a plurality of streams of the mixture that form a plume once exited the outlet orifices, wherein an angle of the plume does not exceed 5 degrees.

Drugs covered by this patent

Patent Metadata

Patent number
EP3851142A1
Jurisdiction
EP
Classification
Expires
2021-07-21
Drug substance claim
No
Drug product claim
No
Assignee
Impel Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.